0d8829713b554f1aed642aeea2d912fd  sfae295.pdf
bde44a0f03dcbd4f018c8af11a01c8ce5d3f7236  sfae295.pdf
264cbbf6b0ea230d1419e7cce2371525d6ca58c948123b4b0f63ab8be4d7d809  sfae295.pdf

Title:           Design and cohort characteristics of TRACK, a prospective study of hyperkalaemia management decision-making
Subject:         DOI: 10.1093/ckj/sfae295 Clinical Kidney Journal, 17, 10, 30-09-2024. Abstract: Guideline-recommended hyperkalaemia management includes dietary potassium (K+) restriction, bicarbonate correction, diuretics and K+ binders with dose reduction of renin–angiotensin–aldosterone system inhibitors as a last resort. The extent to which these recommendations are implemented is uncertain, as real-world data on hyperkalaemia management are limited. The Tracking Treatment Pathways in Adult Patients with Hyperkalemia (TRACK) study is a multinational, prospective, longitudinal study that is being conducted to address this knowledge gap. We report the design and baseline cohort characteristics of this real-world study of hyperkalaemia management decision-making.This study enrolled participants within 21 days of an episode of hyperkalaemia in four European countries (UK, Spain, Germany, Italy) and the USA. During the 12-month follow up, data collected will include participant and healthcare provider characteristics (specialty and practice setting), hyperkalaemia treatment objectives and strategies, rationale for management decisions and indicators of response and patient-reported perceptions of their hyperkalaemia treatment.The enrolled cohort includes 1330 participants, mean age 68 years, of whom 31% were women. At baseline, 6% reported heart failure, 55% chronic kidney disease, 29% both and 9% neither. Most participants (57%) were taking an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker or angiotensin receptor/neprilysin inhibitor at baseline. Mineralocorticoid receptor antagonist use was lower (14%).

The prospective TRACK study will shed light on practitioners’ hyperkalaemia management decision-making and assess the impact of their decisions on hyperkalaemia recurrence. Understanding practitioners’ underlying thought processes will facilitate efforts to improve hyperkalaemia management.
ClinicalTrials.gov: NCT05408039

Keywords:        chronic kidney disease, heart failure, hyperkalaemia management, RAASi, real-world evidence
Author:          Hsia Judith, Shivappa Nitin, Bakhai Ameet, Bover Jordi, Butler Javed, Ferraro Pietro Manuel, Fried Linda, Schneider Markus P., Tangri Navdeep, Winkelmayer Wolfgang C., Bishop Meredith, Chen Hungta, Sundin Anna-Karin, Bonaca Marc P.
Creator:         OUP
Producer:        Acrobat Distiller 10.0.0 (Windows)
CreationDate:    Fri Oct 25 04:44:41 2024 CEST
ModDate:         Fri Oct 25 04:45:12 2024 CEST
Custom Metadata: yes
Metadata Stream: yes
Tagged:          yes
UserProperties:  no
Suspects:        no
Form:            none
JavaScript:      no
Pages:           9
Encrypted:       no
Page size:       612.284 x 790.866 pts
Page rot:        0
File size:       614052 bytes
Optimized:       yes
PDF version:     1.3


name                                 type              encoding         emb sub uni object ID
------------------------------------ ----------------- ---------------- --- --- --- ---------
PFEDFA+MTSY                          Type 1C           Custom           yes yes yes   1194  0
PFEBJJ+CaeciliaLTStd-Bold            Type 1C           WinAnsi          yes yes no    1199  0
PFEDEP+CaeciliaLTStd-Heavy           Type 1C           WinAnsi          yes yes no    1202  0
PFEBJG+CaeciliaLTStd-Italic          Type 1C           WinAnsi          yes yes no    1205  0
PFEBJI+CaeciliaLTStd-Roman           Type 1C           Custom           yes yes yes   1208  0
PFEBJH+dummy-space                   Type 1C           WinAnsi          yes yes no    1213  0
PFEDMO+RMTMI                         Type 1C           Custom           yes yes yes    120  0


Jhove (Rel. 1.28.0, 2023-05-18)
 Date: 2025-06-12 02:41:52 CEST
 RepresentationInformation: sfae295.pdf
  ReportingModule: PDF-hul, Rel. 1.12.4 (2023-03-16)
  LastModified: 2025-06-11 18:21:49 CEST
  Size: 614052
  Format: PDF
  Version: 1.3
  Status: Well-Formed, but not valid
  SignatureMatches:
   PDF-hul
  ErrorMessage: Invalid indirect destination - referenced object 'bib13-b' cannot be found
   ID: PDF-HUL-149
  ErrorMessage: Invalid indirect destination - referenced object 'bib8-b' cannot be found
   ID: PDF-HUL-149
  ErrorMessage: edu.harvard.hul.ois.jhove.module.pdf.PdfInvalidException: Invalid indirect destination - referenced object 'bib13-b' cannot be found
   ID: PDF-HUL-122
   Offset: 485721
  ErrorMessage: edu.harvard.hul.ois.jhove.module.pdf.PdfInvalidException: Invalid indirect destination - referenced object 'bib8-b' cannot be found
   ID: PDF-HUL-122
   Offset: 485721
  MIMEtype: application/pdf
  Profile: Linearized PDF, Tagged PDF
  PDFMetadata: 
   Objects: 1277
   FreeObjects: 1
   IncrementalUpdates: 1
   DocumentCatalog: 
    ViewerPreferences: 
     HideToolbar: false
     HideMenubar: false
     HideWindowUI: false
     FitWindow: false
     CenterWindow: false
     DisplayDocTitle: true
     NonFullScreenPageMode: UseNone
     Direction: L2R
     ViewArea: CropBox
     ViewClip: CropBox
     PrintArea: CropBox
     PageClip: CropBox
    PageLayout: OneColumn
    PageMode: UseOutlines
    Language: English
    Outlines: 
     Item: 
      Title: INTRODUCTION
      Destination: section*.2
     Item: 
      Title: MATERIALS AND METHODS
      Destination: section*.4
     Item: 
      Title: Patient and healthcare provider characteristics
      Destination: section*.6
     Item: 
      Title: Data collection during follow-up
      Destination: section*.8
     Item: 
      Title: Statistical methods
      Destination: section*.10
     Item: 
      Title: RESULTS
      Destination: section*.12
     Item: 
      Title: Healthcare providers
      Destination: section*.14
     Item: 
      Title: DISCUSSION
      Destination: section*.16
     Item: 
      Title: Supplementary data
      Destination: section*.18
     Item: 
      Title: ACKNOWLEDGEMENTS
      Destination: section*.20
     Item: 
      Title: FUNDING
      Destination: section*.22
     Item: 
      Title: AUTHORS’ CONTRIBUTIONS
      Destination: section*.24
     Item: 
      Title: DATA AVAILABILITY STATEMENT
      Destination: section*.26
     Item: 
      Title: CONFLICT OF INTEREST STATEMENT
      Destination: section*.28
     Item: 
      Title: REFERENCES
      Destination: section*.30
   Info: 
    Title: Design and cohort characteristics of TRACK, a prospective study of hyperkalaemia management decision-making
    Author: Hsia Judith, Shivappa Nitin, Bakhai Ameet, Bover Jordi, Butler Javed, Ferraro Pietro Manuel, Fried Linda, Schneider Markus P., Tangri Navdeep, Winkelmayer Wolfgang C., Bishop Meredith, Chen Hungta, Sundin Anna-Karin, Bonaca Marc P.
    Subject: DOI: 10.1093/ckj/sfae295 Clinical Kidney Journal, 17, 10, 30-09-2024. Abstract: Guideline-recommended hyperkalaemia management includes dietary potassium (K+) restriction, bicarbonate correction, diuretics and K+ binders with dose reduction of renin–angiotensin–aldosterone system inhibitors as a last resort. The extent to which these recommendations are implemented is uncertain, as real-world data on hyperkalaemia management are limited. The Tracking Treatment Pathways in Adult Patients with Hyperkalemia (TRACK) study is a multinational, prospective, longitudinal study that is being conducted to address this knowledge gap. We report the design and baseline cohort characteristics of this real-world study of hyperkalaemia management decision-making.This study enrolled participants within 21 days of an episode of hyperkalaemia in four European countries (UK, Spain, Germany, Italy) and the USA. During the 12-month follow up, data collected will include participant and healthcare provider characteristics (specialty and practice setting), hyperkalaemia treatment objectives and strategies, rationale for management decisions and indicators of response and patient-reported perceptions of their hyperkalaemia treatment.The enrolled cohort includes 1330 participants, mean age 68 years, of whom 31% were women. At baseline, 6% reported heart failure, 55% chronic kidney disease, 29% both and 9% neither. Most participants (57%) were taking an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker or angiotensin receptor/neprilysin inhibitor at baseline. Mineralocorticoid receptor antagonist use was lower (14%).

The prospective TRACK study will shed light on practitioners’ hyperkalaemia management decision-making and assess the impact of their decisions on hyperkalaemia recurrence. Understanding practitioners’ underlying thought processes will facilitate efforts to improve hyperkalaemia management.
ClinicalTrials.gov: NCT05408039

    Keywords: chronic kidney disease, heart failure, hyperkalaemia management, RAASi, real-world evidence
    Creator: OUP
    Producer: Acrobat Distiller 10.0.0 (Windows)
    CreationDate: Fri Oct 25 05:14:41 CEST 2024
    ModDate: Fri Oct 25 05:15:12 CEST 2024
   ID: 0x20636e74be5c7091c3ea679abb4f8ee3, 0x012c4de2cb029fadff49d6378b9f55e5
   Filters: 
    FilterPipeline: FlateDecode
    FilterPipeline: DCTDecode
   Images: 
    Image: 
     NisoImageMetadata: 
      FormatName: image/jpg
      CompressionScheme: JPEG
      ImageWidth: 143
      ImageHeight: 151
      ColorSpace: CMYK
      BitsPerSample: 8
      BitsPerSampleUnit: integer
    Image: 
     NisoImageMetadata: 
      FormatName: image/png
      ImageWidth: 23
      ImageHeight: 23
      ColorSpace: black is zero
      BitsPerSample: 8
      BitsPerSampleUnit: integer
     Filter: FlateDecode
    Image: 
     NisoImageMetadata: 
      FormatName: image/jpg
      CompressionScheme: JPEG
      ImageWidth: 1063
      ImageHeight: 380
      ColorSpace: RGB
      BitsPerSample: 8
      BitsPerSampleUnit: integer
    Image: 
     NisoImageMetadata: 
      FormatName: image/png
      ImageWidth: 495
      ImageHeight: 997
      BitsPerSample: 8
      BitsPerSampleUnit: integer
     Filter: FlateDecode
    Image: 
     NisoImageMetadata: 
      FormatName: image/png
      ImageWidth: 865
      ImageHeight: 873
      BitsPerSample: 8
      BitsPerSampleUnit: integer
     Filter: FlateDecode
    Image: 
     NisoImageMetadata: 
      FormatName: image/png
      ImageWidth: 1354
      ImageHeight: 3
      BitsPerSample: 8
      BitsPerSampleUnit: integer
     Filter: FlateDecode
    Image: 
     NisoImageMetadata: 
      FormatName: image/png
      ImageWidth: 865
      ImageHeight: 126
      BitsPerSample: 8
      BitsPerSampleUnit: integer
     Filter: FlateDecode
   Fonts: 
    Type1: 
     Font: 
      BaseFont: PFEDEP+CaeciliaLTStd-Heavy
      FontSubset: true
      FirstChar: 49
      LastChar: 146
      FontDescriptor: 
       FontName: PFEDEP+CaeciliaLTStd-Heavy
       Flags: Nonsymbolic, ForceBold
       FontBBox: -170, -277, 1146, 970
       FontFile3: true
      Encoding: WinAnsiEncoding
     Font: 
      BaseFont: PFEBJG+CaeciliaLTStd-Italic
      FontSubset: true
      FirstChar: 46
      LastChar: 121
      FontDescriptor: 
       FontName: PFEBJG+CaeciliaLTStd-Italic
       Flags: Serif, Nonsymbolic, Italic
       FontBBox: -166, -270, 1053, 915
       FontFile3: true
      Encoding: WinAnsiEncoding
     Font: 
      BaseFont: PFEBJI+CaeciliaLTStd-Roman
      FontSubset: true
      FirstChar: 2
      LastChar: 252
      FontDescriptor: 
       FontName: PFEBJI+CaeciliaLTStd-Roman
       Flags: Serif, Symbolic
       FontBBox: -167, -270, 1136, 926
       FontFile3: true
      EncodingDictionary: 
       Differences: true
      ToUnicode: true
     Font: 
      BaseFont: PFEDMO+RMTMI
      FontSubset: true
      FirstChar: 60
      LastChar: 62
      FontDescriptor: 
       FontName: PFEDMO+RMTMI
       Flags: Symbolic, Italic
       FontBBox: 0, -213, 987, 680
       FontFile3: true
      EncodingDictionary: 
       Differences: true
      ToUnicode: true
     Font: 
      BaseFont: PFEDFA+MTSY
      FontSubset: true
      FirstChar: 2
      LastChar: 61
      FontDescriptor: 
       FontName: PFEDFA+MTSY
       Flags: Symbolic
       FontBBox: 0, -954, 1043, 796
       FontFile3: true
      EncodingDictionary: 
       Differences: true
      ToUnicode: true
     Font: 
      BaseFont: PFEBJH+dummy-space
      FontSubset: true
      FirstChar: 32
      LastChar: 32
      FontDescriptor: 
       FontName: PFEBJH+dummy-space
       Flags: Nonsymbolic
       FontBBox: 0, 0, 0, 0
       FontFile3: true
      Encoding: WinAnsiEncoding
     Font: 
      BaseFont: PFEBJJ+CaeciliaLTStd-Bold
      FontSubset: true
      FirstChar: 44
      LastChar: 121
      FontDescriptor: 
       FontName: PFEBJJ+CaeciliaLTStd-Bold
       Flags: Serif, Nonsymbolic, ForceBold
       FontBBox: -166, -273, 1141, 938
       FontFile3: true
      Encoding: WinAnsiEncoding
   XMP: <x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="XMP Core 5.1.2">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/">
         <xmp:CreateDate>2024-10-25T08:14:41+05:30</xmp:CreateDate>
         <xmp:ModifyDate>2024-10-25T08:15:12+05:30</xmp:ModifyDate>
         <xmp:MetadataDate>2024-10-25T08:15:12+05:30</xmp:MetadataDate>
         <xmp:CreatorTool>OUP</xmp:CreatorTool>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/">
         <pdf:Producer>Acrobat Distiller 10.0.0 (Windows)</pdf:Producer>
         <pdf:Keywords>chronic kidney disease, heart failure, hyperkalaemia management, RAASi, real-world evidence</pdf:Keywords>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:jav="http://www.niso.org/schemas/jav/1.0/">
         <jav:journal_article_version>VoR</jav:journal_article_version>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:pdfx="http://ns.adobe.com/pdfx/1.3/">
         <pdfx:doi>10.1093/ckj/sfae295</pdfx:doi>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:prism="http://prismstandard.org/namespaces/basic/3.0/">
         <prism:issn>2048-8513</prism:issn>
         <prism:publicationName>Clinical Kidney Journal</prism:publicationName>
         <prism:aggregationType>journal</prism:aggregationType>
         <prism:volume>17</prism:volume>
         <prism:doi>10.1093/ckj/sfae295</prism:doi>
         <prism:url>https://doi.org/10.1093/ckj/sfae295</prism:url>
         <prism:copyright>© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</prism:copyright>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:dc="http://purl.org/dc/elements/1.1/">
         <dc:rightsHolder>All Rights Reserved</dc:rightsHolder>
         <dc:format>application/pdf</dc:format>
         <dc:identifier>doi:10.1093/ckj/sfae295</dc:identifier>
         <dc:rights>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</rdf:li>
            </rdf:Alt>
         </dc:rights>
         <dc:contributor>
            <rdf:Seq>
               <rdf:li>Hsia Judith</rdf:li>
               <rdf:li>Shivappa Nitin</rdf:li>
               <rdf:li>Bakhai Ameet</rdf:li>
               <rdf:li>Bover Jordi</rdf:li>
               <rdf:li>Butler Javed</rdf:li>
               <rdf:li>Ferraro Pietro Manuel</rdf:li>
               <rdf:li>Fried Linda</rdf:li>
               <rdf:li>Schneider Markus P.</rdf:li>
               <rdf:li>Tangri Navdeep</rdf:li>
               <rdf:li>Winkelmayer Wolfgang C.</rdf:li>
               <rdf:li>Bishop Meredith</rdf:li>
               <rdf:li>Chen Hungta</rdf:li>
               <rdf:li>Sundin Anna-Karin</rdf:li>
               <rdf:li>Bonaca Marc P.</rdf:li>
            </rdf:Seq>
         </dc:contributor>
         <dc:publisher>
            <rdf:Bag>
               <rdf:li>Oxford University Press</rdf:li>
            </rdf:Bag>
         </dc:publisher>
         <dc:description>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">DOI: 10.1093/ckj/sfae295 Clinical Kidney Journal, 17, 10, 30-09-2024. Abstract: Guideline-recommended hyperkalaemia management includes dietary potassium (K&amp;#x002B;) restriction, bicarbonate correction, diuretics and K&amp;#x002B; binders with dose reduction of renin&amp;#x2013;angiotensin&amp;#x2013;aldosterone system inhibitors as a last resort. The extent to which these recommendations are implemented is uncertain, as real-world data on hyperkalaemia management are limited. The Tracking Treatment Pathways in Adult Patients with Hyperkalemia (TRACK) study is a multinational, prospective, longitudinal study that is being conducted to address this knowledge gap. We report the design and baseline cohort characteristics of this real-world study of hyperkalaemia management decision-making.This study enrolled participants within 21&amp;#x00A0;days of an episode of hyperkalaemia in four European countries (UK, Spain, Germany, Italy) and the USA. During the 12-month follow up, data collected will include participant and healthcare provider characteristics (specialty and practice setting), hyperkalaemia treatment objectives and strategies, rationale for management decisions and indicators of response and patient-reported perceptions of their hyperkalaemia treatment.The enrolled cohort includes 1330 participants, mean age 68&amp;#x00A0;years, of whom 31&amp;#x0025; were women. At baseline, 6&amp;#x0025; reported heart failure, 55&amp;#x0025; chronic kidney disease, 29&amp;#x0025; both and 9&amp;#x0025; neither. Most participants (57&amp;#x0025;) were taking an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker or angiotensin receptor/neprilysin inhibitor at baseline. Mineralocorticoid receptor antagonist use was lower (14&amp;#x0025;).&#xA;&#xA;The prospective TRACK study will shed light on practitioners&amp;#x2019; hyperkalaemia management decision-making and assess the impact of their decisions on hyperkalaemia recurrence. Understanding practitioners&amp;#x2019; underlying thought processes will facilitate efforts to improve hyperkalaemia management.&#xA;ClinicalTrials.gov: NCT05408039&#xA;</rdf:li>
            </rdf:Alt>
         </dc:description>
         <dc:subject>
            <rdf:Bag>
               <rdf:li>chronic kidney disease</rdf:li>
               <rdf:li>heart failure</rdf:li>
               <rdf:li>hyperkalaemia management</rdf:li>
               <rdf:li>RAASi</rdf:li>
               <rdf:li>real-world evidence</rdf:li>
            </rdf:Bag>
         </dc:subject>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">Design and cohort characteristics of TRACK, a prospective study of hyperkalaemia management decision-making</rdf:li>
            </rdf:Alt>
         </dc:title>
         <dc:creator>
            <rdf:Seq>
               <rdf:li>Hsia Judith, Shivappa Nitin, Bakhai Ameet, Bover Jordi, Butler Javed, Ferraro Pietro Manuel, Fried Linda, Schneider Markus P., Tangri Navdeep, Winkelmayer Wolfgang C., Bishop Meredith, Chen Hungta, Sundin Anna-Karin, Bonaca Marc P.</rdf:li>
            </rdf:Seq>
         </dc:creator>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/">
         <xmpMM:DocumentID>uuid:46275735-5fe2-3f76-87b5-ba8118db2b64</xmpMM:DocumentID>
         <xmpMM:InstanceID>uuid:b58512da-5364-4d36-8853-2a025a7e1cd3</xmpMM:InstanceID>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:xmpRights="http://ns.adobe.com/xap/1.0/rights/">
         <xmpRights:Marked>True</xmpRights:Marked>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
   Pages: 
    Page: 
     Label: 1
     Annotations: 
      Annotation: 
       Subtype: Link
       Rect: 62, 683, 116, 694
      Annotation: 
       Subtype: Link
       Rect: 314, 709, 426, 719
      Annotation: 
       Subtype: Link
       Rect: 134, 516, 148, 533
      Annotation: 
       Subtype: Link
       Rect: 146, 522, 153, 534
       Destination: 1174
      Annotation: 
       Subtype: Link
       Rect: 253, 522, 260, 534
       Destination: 1174
      Annotation: 
       Subtype: Link
       Rect: 355, 522, 362, 534
       Destination: 1174
      Annotation: 
       Subtype: Link
       Rect: 436, 522, 443, 534
       Destination: 1174
      Annotation: 
       Subtype: Link
       Rect: 526, 516, 540, 533
      Annotation: 
       Subtype: Link
       Rect: 538, 522, 545, 534
       Destination: 1174
      Annotation: 
       Subtype: Link
       Rect: 202, 498, 216, 515
      Annotation: 
       Subtype: Link
       Rect: 214, 504, 221, 516
       Destination: 1174
      Annotation: 
       Subtype: Link
       Rect: 297, 504, 304, 516
       Destination: 1174
      Annotation: 
       Subtype: Link
       Rect: 437, 504, 445, 516
       Destination: 1174
      Annotation: 
       Subtype: Link
       Rect: 162, 486, 169, 499
       Destination: 1174
      Annotation: 
       Subtype: Link
       Rect: 339, 486, 351, 499
       Destination: 1174
      Annotation: 
       Subtype: Link
       Rect: 461, 486, 474, 499
       Destination: 1174
      Annotation: 
       Subtype: Link
       Rect: 146, 468, 153, 481
       Destination: 1174
      Annotation: 
       Subtype: Link
       Rect: 283, 468, 295, 481
       Destination: 1174
      Annotation: 
       Subtype: Link
       Rect: 419, 468, 426, 481
       Destination: 1174
      Annotation: 
       Subtype: Link
       Rect: 189, 363, 268, 372
      Annotation: 
       Subtype: Link
       Rect: 328, 363, 374, 372
      Annotation: 
       Subtype: Link
       Rect: 218, 71, 374, 80
      Annotation: 
       Subtype: Link
       Rect: 435, 61, 537, 71
     Thumb: true
    Page: 
     Label: 2
     Annotations: 
      Annotation: 
       Subtype: Link
       Rect: 127, 401, 133, 411
       Destination: 75
      Annotation: 
       Subtype: Link
       Rect: 108, 380, 115, 390
       Destination: 75
      Annotation: 
       Subtype: Link
       Rect: 265, 359, 271, 369
       Destination: 75
      Annotation: 
       Subtype: Link
       Rect: 273, 359, 280, 369
       Destination: 75
      Annotation: 
       Subtype: Link
       Rect: 143, 348, 149, 359
       Destination: 75
      Annotation: 
       Subtype: Link
       Rect: 101, 306, 107, 317
       Destination: 75
      Annotation: 
       Subtype: Link
       Rect: 103, 222, 110, 233
       Destination: 75
      Annotation: 
       Subtype: Link
       Rect: 111, 222, 118, 233
       Destination: 75
      Annotation: 
       Subtype: Link
       Rect: 526, 323, 532, 334
       Destination: 16
      Annotation: 
       Subtype: Link
       Rect: 375, 281, 381, 292
       Destination: 16
      Annotation: 
       Subtype: Link
       Rect: 480, 271, 486, 281
       Destination: 21
      Annotation: 
       Subtype: Link
       Rect: 436, 218, 442, 228
       Destination: 16
      Annotation: 
       Subtype: Link
       Rect: 446, 186, 457, 197
       Destination: 75
     Thumb: true
    Page: 
     Label: 3
     Annotations: 
      Annotation: 
       Subtype: Link
       Rect: 87, 177, 93, 188
       Destination: 16
      Annotation: 
       Subtype: Link
       Rect: 202, 135, 293, 145
      Annotation: 
       Subtype: Link
       Rect: 91, 61, 101, 72
       Destination: 75
     Thumb: true
    Page: 
     Label: 4
     Annotations: 
      Annotation: 
       Subtype: Link
       Rect: 396, 108, 402, 119
       Destination: 21
     Thumb: true
    Page: 
     Label: 5
     Annotations: 
      Annotation: 
       Subtype: Link
       Rect: 490, 58, 496, 68
       Destination: 28
     Thumb: true
    Page: 
     Label: 6
     Annotations: 
      Annotation: 
       Subtype: Link
       Rect: 301, 585, 307, 595
       Destination: 48
      Annotation: 
       Subtype: Link
       Rect: 452, 585, 458, 595
       Destination: 48
      Annotation: 
       Subtype: Link
       Rect: 123, 575, 128, 585
       Destination: 48
      Annotation: 
       Subtype: Link
       Rect: 301, 575, 307, 585
       Destination: 48
      Annotation: 
       Subtype: Link
       Rect: 452, 575, 457, 585
       Destination: 48
      Annotation: 
       Subtype: Link
       Rect: 86, 516, 92, 526
       Destination: 48
      Annotation: 
       Subtype: Link
       Rect: 297, 516, 303, 526
       Destination: 48
      Annotation: 
       Subtype: Link
       Rect: 452, 516, 458, 526
       Destination: 48
      Annotation: 
       Subtype: Link
       Rect: 104, 456, 109, 466
       Destination: 48
      Annotation: 
       Subtype: Link
       Rect: 301, 456, 307, 466
       Destination: 48
      Annotation: 
       Subtype: Link
       Rect: 452, 456, 457, 466
       Destination: 48
      Annotation: 
       Subtype: Link
       Rect: 297, 396, 303, 406
       Destination: 48
      Annotation: 
       Subtype: Link
       Rect: 443, 396, 449, 406
       Destination: 48
      Annotation: 
       Subtype: Link
       Rect: 288, 108, 294, 118
       Destination: 48
      Annotation: 
       Subtype: Link
       Rect: 499, 80, 509, 91
       Destination: 75
      Annotation: 
       Subtype: Link
       Rect: 511, 80, 521, 91
       Destination: 75
     Thumb: true
    Page: 
     Label: 7
     Annotations: 
      Annotation: 
       Subtype: Link
       Rect: 194, 685, 204, 696
       Destination: 75
      Annotation: 
       Subtype: Link
       Rect: 82, 528, 93, 538
       Destination: 75
      Annotation: 
       Subtype: Link
       Rect: 133, 444, 144, 454
       Destination: 75
      Annotation: 
       Subtype: Link
       Rect: 238, 349, 249, 360
       Destination: 75
      Annotation: 
       Subtype: Link
       Rect: 175, 66, 185, 76
       Destination: 112
      Annotation: 
       Subtype: Link
       Rect: 188, 66, 198, 76
       Destination: 112
      Annotation: 
       Subtype: Link
       Rect: 445, 611, 522, 621
     Thumb: true
    Page: 
     Label: 8
     Annotations: 
      Annotation: 
       Subtype: Link
       Rect: 63, 274, 71, 285
       Destination: 1
      Annotation: 
       Subtype: Link
       Rect: 52, 232, 299, 255
      Annotation: 
       Subtype: Link
       Rect: 63, 222, 71, 233
       Destination: 1
      Annotation: 
       Subtype: Link
       Rect: 52, 190, 299, 213
      Annotation: 
       Subtype: Link
       Rect: 63, 180, 71, 191
       Destination: 1
      Annotation: 
       Subtype: Link
       Rect: 52, 158, 299, 181
      Annotation: 
       Subtype: Link
       Rect: 63, 149, 71, 159
       Destination: 1
      Annotation: 
       Subtype: Link
       Rect: 125, 118, 285, 128
      Annotation: 
       Subtype: Link
       Rect: 63, 107, 71, 118
       Destination: 1
      Annotation: 
       Subtype: Link
       Rect: 52, 54, 299, 77
      Annotation: 
       Subtype: Link
       Rect: 314, 717, 322, 727
       Destination: 1
      Annotation: 
       Subtype: Link
       Rect: 329, 674, 570, 697
      Annotation: 
       Subtype: Link
       Rect: 314, 664, 322, 675
       Destination: 1
      Annotation: 
       Subtype: Link
       Rect: 329, 621, 570, 644
      Annotation: 
       Subtype: Link
       Rect: 314, 612, 322, 622
       Destination: null
      Annotation: 
       Subtype: Link
       Rect: 314, 570, 322, 581
       Destination: 1
      Annotation: 
       Subtype: Link
       Rect: 329, 517, 570, 571
      Annotation: 
       Subtype: Link
       Rect: 314, 507, 326, 518
       Destination: 1
      Annotation: 
       Subtype: Link
       Rect: 329, 475, 570, 498
      Annotation: 
       Subtype: Link
       Rect: 314, 465, 326, 476
       Destination: 16
      Annotation: 
       Subtype: Link
       Rect: 349, 445, 504, 455
      Annotation: 
       Subtype: Link
       Rect: 314, 424, 326, 434
       Destination: 48
      Annotation: 
       Subtype: Link
       Rect: 329, 349, 570, 393
      Annotation: 
       Subtype: Link
       Rect: 314, 330, 326, 340
       Destination: null
      Annotation: 
       Subtype: Link
       Rect: 412, 298, 548, 309
      Annotation: 
       Subtype: Link
       Rect: 314, 288, 326, 298
       Destination: 48
      Annotation: 
       Subtype: Link
       Rect: 329, 255, 570, 278
      Annotation: 
       Subtype: Link
       Rect: 314, 246, 326, 256
       Destination: 66
      Annotation: 
       Subtype: Link
       Rect: 329, 203, 570, 226
      Annotation: 
       Subtype: Link
       Rect: 314, 194, 326, 204
       Destination: 66
      Annotation: 
       Subtype: Link
       Rect: 329, 161, 570, 184
      Annotation: 
       Subtype: Link
       Rect: 314, 152, 326, 162
       Destination: 66
      Annotation: 
       Subtype: Link
       Rect: 329, 109, 570, 132
      Annotation: 
       Subtype: Link
       Rect: 314, 99, 326, 110
       Destination: 66
      Annotation: 
       Subtype: Link
       Rect: 391, 58, 519, 68
     Thumb: true
    Page: 
     Label: 9
     Annotations: 
      Annotation: 
       Subtype: Link
       Rect: 62, 717, 74, 727
       Destination: 66
      Annotation: 
       Subtype: Link
       Rect: 78, 675, 204, 685
      Annotation: 
       Subtype: Link
       Rect: 313, 717, 325, 727
       Destination: 66
      Annotation: 
       Subtype: Link
       Rect: 329, 685, 482, 696
      Annotation: 
       Subtype: Link
       Rect: 218, 37, 374, 46
      Annotation: 
       Subtype: Link
       Rect: 435, 27, 537, 37
     Thumb: true
  Checksum: 69e34dc1
   Type: CRC32
  Checksum: 0d8829713b554f1aed642aeea2d912fd
   Type: MD5
  Checksum: bde44a0f03dcbd4f018c8af11a01c8ce5d3f7236
   Type: SHA-1
  Checksum: 264cbbf6b0ea230d1419e7cce2371525d6ca58c948123b4b0f63ab8be4d7d809
   Type: SHA-256